Clinical value of fluorine-18 2-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in bladder cancer

Journal of Clinical Oncology

Volumn 28, Issue 25, 2010, Pages 3973-3978

  Apolo, Andrea B ^a   Riches, Jamie ^a   Schöder, Heiko ^a   Akin, Oguz ^a   Trout, Alisa ^a   Milowsky, Matthew I ^a   Bajorin, Dean F ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; DIAGNOSTIC AGENT;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLADDER BIOPSY; BLADDER CANCER; CANCER DIAGNOSIS; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; FEMALE; HUMAN; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; VALIDATION PROCESS; BLADDER TUMOR; COMPUTER ASSISTED EMISSION TOMOGRAPHY; EVALUATION; METHODOLOGY; MIDDLE AGED; PATIENT CARE PLANNING; QUESTIONNAIRE;

AGED; AGED, 80 AND OVER; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MIDDLE AGED; PATIENT CARE PLANNING; POSITRON-EMISSION TOMOGRAPHY; QUESTIONNAIRES; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, EMISSION-COMPUTED; URINARY BLADDER NEOPLASMS;

EID: 77957553224     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.28.7052     Document Type: Article

References (23)

1. Yaman O, Baltaci S, Arikan N, et al: Staging with computed tomography, transrectal ultrasonography and transurethral resection of bladder tumour: Comparison with final pathological stage in invasive bladder carcinoma. Br J Urol 78:197-200, 1996 (Pubitemid 27407895)
2. Paik ML, Scolieri MJ, Brown SL, et al: Limitations of computerized tomography in staging invasive bladder cancer before radical cystectomy. J Urol 163:1693-1696, 2000 (Pubitemid 30366715)
3. Buy JN, Moss AA, Guinet C, et al: MR staging of bladder carcinoma: Correlation with pathologic findings. Radiology 169:695-700, 1988
4. Czernin J, Phelps ME: Positron emission tomography scanning: Current and future applications. Annu Rev Med 53:89-112, 2002 (Pubitemid 34177873)
5. Rohren EM, Turkington TG, Coleman RE: Clinical applications of PET in oncology. Radiology 231:305-332, 2004 (Pubitemid 38552885)
6. Podoloff DA, Ball DW, Ben-Josef E, et al: NCCN task force: Clinical utility of PET in a variety of tumor types. J Natl Compr Canc Netw 7:S1-S26, 2009 (suppl 2)
7. Kibel AS, Dehdashti F, Katz MD, et al: Prospective study of [18F]fluorodeoxyglucose positron emission tomography/computed tomography for staging of muscle-invasive bladder carcinoma. J Clin Oncol 27:4314-4320, 2009
8. Drieskens O, Oyen R, Van Poppel H, et al: FDG-PET for preoperative staging of bladder cancer. Eur J Nucl Med Mol Imaging 32:1412-1417, 2005 (Pubitemid 41746845)
9. Hillner BE, Siegel BA, Liu D, et al: Impact of positron emission tomography/computed tomography and positron emission tomography (PET) alone on expected management of patients with cancer: Initial results from the National Oncologic PET Registry. J Clin Oncol 26:2155-2161, 2008
10. Hillner BE, Siegel BA, Shields AF, et al: Relationship between cancer type and impact of PET and PET/CT on intended management: Findings of the national oncologic PET registry. J Nucl Med 49:1928-1935, 2008
11. Hoekstra CJ, Stroobants SG, Smit EF, et al: Prognostic relevance of response evaluation using [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with locally advanced non-small-cell lung cancer. J Clin Oncol 23:8362-8370, 2005
12. Kosuda S, Kison PV, Greenough R, et al: Preliminary assessment of fluorine-18 fluorodeoxyglucose positron emission tomography in patients with bladder cancer. Eur J Nucl Med 24:615-620, 1997 (Pubitemid 27299740)
13. Heicappell R, Müller-Mattheis V, Reinhardt M, et al: Staging of pelvic lymph nodes in neoplasms of the bladder and prostate by positron emission tomography with 2-[(18)F]-2-deoxy-D-glucose. Eur Urol 36:582-587, 1999
14. Bachor R, Kotzerke J, Reske SN, et al: Lymph node staging of bladder neck carcinoma with positron emission tomography. Urologe A 38:46-50, 1999 (Pubitemid 29146329)
15. Liu IJ, Lai YH, Espiritu JI, et al: Evaluation of fluorodeoxyglucose positron emission tomography imaging in metastatic transitional cell carcinoma with and without prior chemotherapy. Urol Int 77:69-75, 2006 (Pubitemid 44034422)
16. Jadvar H, Quan V, Henderson RW, et al: [F-18]-Fluorodeoxyglucose PET and PET-CT in diagnostic imaging evaluation of locally recurrent and metastatic bladder transitional cell carcinoma. Int J Clin Oncol 13:42-47, 2008 (Pubitemid 351326281)
17. Swinnen G, Maes A, Pottel H, et al: FDG-PET/CT for the preoperative lymph node staging of invasive bladder cancer. Eur Urol [epub ahead of print on May 18, 2009]
18. Moulin-Romsee G, Spaepen K, Stroobants S, et al: Non-Hodgkin lymphoma: Retrospective study on the cost-effectiveness of early treatment response assessment by FDG-PET. Eur J Nucl Med Mol Imaging 35:1074-1080, 2008
19. Yen RF, Yen MF, Hong RL, et al: The cost-utility analysis of 18-fluoro-2-deoxyglucose positron emission tomography in the diagnosis of recurrent nasopharyngeal carcinoma. Acad Radiol 16:54-60, 2009
20. Beggs AD, Hain SF, Curran KM, et al: FDG-PET as a "metabolic biopsy" tool in non-lung lesions with indeterminate biopsy. Eur J Nucl Med Mol Imaging 29:542-546, 2002 (Pubitemid 44763143)
21. Stephens AW, Gonin R, Hutchins GD, et al: Positron emission tomography evaluation of residual radiographic abnormalities in postchemotherapy germ cell tumor patients. J Clin Oncol 14:1637-1641, 1996 (Pubitemid 26134222)
22. De Santis M, Becherer A, Bokemeyer C, et al: 2-18fluoro-deoxy-D-glucose positron emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma: An update of the prospective multicentric SEMPET trial. J Clin Oncol 22:1034-1039, 2004 (Pubitemid 41095035)
23. Gambhir SS, Czernin J, Schwimmer J, et al: A tabulated summary of the FDG PET literature. J Nucl Med 42:1S-93S, 2001 (suppl)